September 13th 2024
Eric Jonasch, MD, discusses preliminary findings from a trial investigating NKT-2152 in previously treated advanced clear cell renal cell carcinoma.
January 8th 2024
Eric Jonasch, MD, discusses the goals of a meeting sponsored by the International Kidney Cancer Coalition that will focus on patient advocacy in GU malignancies.
December 1st 2023
Eric Jonasch, MD, discusses the evolution of belzutifan in cancer care, highlighting the agent’s potential for the treatment of patients with renal cell carcinoma.
November 22nd 2022
Eric Jonasch, MD, discusses the promise of the hypoxia inducible factor-2 alpha inhibitor belzutifan in metastatic renal cell carcinoma.
November 10th 2022
Shared insight on the evolving treatment landscape of renal cell carcinoma and expectations for future evolution in the paradigm.
Before closing out there review of non–clear cell RCC management, expert oncologists highlight novel therapeutic strategies and ongoing clinical trials.
November 4th 2022
Eric Jonasch, MD, discusses the exploration of cabozantinib in the neoadjuvant setting in renal cell carcinoma.
November 3rd 2022
Moving on to discuss the management of non–clear cell renal cell carcinoma, panelists consider cornerstone treatment options in this setting.
Comprehensive insight to the optimal selection and sequencing of therapy for advanced clear cell RCC in the second-line setting and beyond.
October 27th 2022
Centering their discussion on the second-line setting, expert oncologists review mainstay second-line therapies for advanced clear cell RCC.
Expert perspectives on key clinical trials studying first-line adjuvant therapy in patients with advanced clear cell renal cell carcinoma.
October 20th 2022
Focusing on novel first-line triplet therapy combinations, panelists consider which regimens may find a role in the management of advanced clear cell RCC.
An expert panel reviews novel first-line doublet therapies being studied in patients with advanced clear cell renal cell carcinoma.
October 13th 2022
Before closing out their review of mainstay combination therapy in the first-line setting of advanced clear cell RCC, panelists reflect on available quality of life data.
Focused discussion on brain metastases or sarcomatoid disease in advanced clear cell RCC and the selection of first-line treatment regimens.
October 6th 2022
Shared insight on the importance of sites of metastases and how they may impact first-line treatment selection in advanced clear cell RCC.
Centering conversation on systemic therapy, panelists review trial data behind the first-line combination regimens for patients with advanced clear cell RCC.
September 29th 2022
Comprehensive insight to the role of nephrectomy over systemic therapy in patients who receive a diagnosis of advanced clear cell RCC.
Expert oncologists open their discussion on advanced clear cell RCC by identifying its prevalence and prognoses before moving into treatment considerations.
August 24th 2022
Eric Jonasch, MD, discusses the best patient population when treating with belzutifan in clear cell renal cell carcinoma.